{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine",
                    "control": "5-fluorouracil",
                    "phase": "3",
                    "median survival therapy": "5.7 months",
                    "median survival control": "4.2 months",
                    "one-year survival therapy": "18%",
                    "one-year survival control": "2%",
                    "side effects": "more favorable than 5-fluorouracil",
                    "FDA approval": "1996"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[5.7, 4.2, 18%, 2%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control]",
                "outcomes": "['5.7', '4.2']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "6.4 months",
                    "median survival control": "6 months",
                    "one-year survival therapy": "24%",
                    "one-year survival control": "19%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2005"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[6.4, 6, 24%, 19%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "6.4 months",
                    "median survival control": "6 months",
                    "one-year survival therapy": "24%",
                    "one-year survival control": "19%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2005"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[6.4, 6, 24%, 19%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "6.4 months",
                    "median survival control": "6 months",
                    "one-year survival therapy": "24%",
                    "one-year survival control": "19%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2005"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[6.4, 6, 24%, 19%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "6.4 months",
                    "median survival control": "6 months",
                    "one-year survival therapy": "24%",
                    "one-year survival control": "19%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2005"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[6.4, 6, 24%, 19%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['8.5', '6.7']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "6.4 months",
                    "median survival control": "6 months",
                    "one-year survival therapy": "24%",
                    "one-year survival control": "19%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2005"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[6.4, 6, 24%, 19%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "6.4 months",
                    "median survival control": "6 months",
                    "one-year survival therapy": "24%",
                    "one-year survival control": "19%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2005"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[6.4, 6, 24%, 19%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['11.1', '6.8']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "6.4 months",
                    "median survival control": "6 months",
                    "one-year survival therapy": "24%",
                    "one-year survival control": "19%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2005"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[6.4, 6, 24%, 19%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['48.4%', '20.6%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "6.4 months",
                    "median survival control": "6 months",
                    "one-year survival therapy": "24%",
                    "one-year survival control": "19%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2005"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[6.4, 6, 24%, 19%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['10', '5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "6.4 months",
                    "median survival control": "6 months",
                    "one-year survival therapy": "24%",
                    "one-year survival control": "19%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2005"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[6.4, 6, 24%, 19%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['36%', '18%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "8.5 months",
                    "median survival control": "6.7 months",
                    "one-year survival therapy": "35%",
                    "one-year survival control": "22%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2013"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[8.5, 6.7, 35%, 22%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "8.5 months",
                    "median survival control": "6.7 months",
                    "one-year survival therapy": "35%",
                    "one-year survival control": "22%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2013"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[8.5, 6.7, 35%, 22%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "8.5 months",
                    "median survival control": "6.7 months",
                    "one-year survival therapy": "35%",
                    "one-year survival control": "22%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2013"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[8.5, 6.7, 35%, 22%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "median survival therapy": "8.5 months",
                    "median survival control": "6.7 months",
                    "one-year survival therapy": "35%",
                    "one-year survival control": "22%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "2013"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[8.5, 6.7, 35%, 22%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['8.5', '6.7']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "FOLFIRINOX",
                    "control": "gemcitabine",
                    "phase": "2/3",
                    "median survival therapy": "11.1 months",
                    "median survival control": "6.8 months",
                    "one-year survival therapy": "48.4%",
                    "one-year survival control": "20.6%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "n/a",
                    "components": "Oxaliplatin, irinotecan, fluorouracil and leucovorin"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[11.1, 6.8, 48.4%, 20.6%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "FOLFIRINOX",
                    "control": "gemcitabine",
                    "phase": "2/3",
                    "median survival therapy": "11.1 months",
                    "median survival control": "6.8 months",
                    "one-year survival therapy": "48.4%",
                    "one-year survival control": "20.6%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "n/a",
                    "components": "Oxaliplatin, irinotecan, fluorouracil and leucovorin"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[11.1, 6.8, 48.4%, 20.6%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "FOLFIRINOX",
                    "control": "gemcitabine",
                    "phase": "2/3",
                    "median survival therapy": "11.1 months",
                    "median survival control": "6.8 months",
                    "one-year survival therapy": "48.4%",
                    "one-year survival control": "20.6%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "n/a",
                    "components": "Oxaliplatin, irinotecan, fluorouracil and leucovorin"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[11.1, 6.8, 48.4%, 20.6%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "FOLFIRINOX",
                    "control": "gemcitabine",
                    "phase": "2/3",
                    "median survival therapy": "11.1 months",
                    "median survival control": "6.8 months",
                    "one-year survival therapy": "48.4%",
                    "one-year survival control": "20.6%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "n/a",
                    "components": "Oxaliplatin, irinotecan, fluorouracil and leucovorin"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[11.1, 6.8, 48.4%, 20.6%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "FOLFIRINOX",
                    "control": "gemcitabine",
                    "phase": "2/3",
                    "median survival therapy": "11.1 months",
                    "median survival control": "6.8 months",
                    "one-year survival therapy": "48.4%",
                    "one-year survival control": "20.6%",
                    "side effects": "less favorable than gemcitabine",
                    "FDA approval": "n/a",
                    "components": "Oxaliplatin, irinotecan, fluorouracil and leucovorin"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[11.1, 6.8, 48.4%, 20.6%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['11.1', '6.8']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "cell encapsulation + ifosfamide",
                    "control": "5-fluorouracil",
                    "phase": "2",
                    "median survival therapy": "10 months",
                    "median survival control": "5 months",
                    "one-year survival therapy": "36%",
                    "one-year survival control": "18%",
                    "side effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA approval": "n/a",
                    "toxicity": "five patients experienced Grade 3 or Grade 4 NCI toxicities with a higher dose of 2 g/m2",
                    "median survival": "9.5 months"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[10, 5, 36%, 18%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "cell encapsulation + ifosfamide",
                    "control": "5-fluorouracil",
                    "phase": "2",
                    "median survival therapy": "10 months",
                    "median survival control": "5 months",
                    "one-year survival therapy": "36%",
                    "one-year survival control": "18%",
                    "side effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA approval": "n/a",
                    "toxicity": "five patients experienced Grade 3 or Grade 4 NCI toxicities with a higher dose of 2 g/m2",
                    "median survival": "9.5 months"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[10, 5, 36%, 18%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "cell encapsulation + ifosfamide",
                    "control": "5-fluorouracil",
                    "phase": "2",
                    "median survival therapy": "10 months",
                    "median survival control": "5 months",
                    "one-year survival therapy": "36%",
                    "one-year survival control": "18%",
                    "side effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA approval": "n/a",
                    "toxicity": "five patients experienced Grade 3 or Grade 4 NCI toxicities with a higher dose of 2 g/m2",
                    "median survival": "9.5 months"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[10, 5, 36%, 18%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "cell encapsulation + ifosfamide",
                    "control": "5-fluorouracil",
                    "phase": "2",
                    "median survival therapy": "10 months",
                    "median survival control": "5 months",
                    "one-year survival therapy": "36%",
                    "one-year survival control": "18%",
                    "side effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA approval": "n/a",
                    "toxicity": "five patients experienced Grade 3 or Grade 4 NCI toxicities with a higher dose of 2 g/m2",
                    "median survival": "9.5 months"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[10, 5, 36%, 18%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "cell encapsulation + ifosfamide",
                    "control": "5-fluorouracil",
                    "phase": "2",
                    "median survival therapy": "10 months",
                    "median survival control": "5 months",
                    "one-year survival therapy": "36%",
                    "one-year survival control": "18%",
                    "side effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA approval": "n/a",
                    "toxicity": "five patients experienced Grade 3 or Grade 4 NCI toxicities with a higher dose of 2 g/m2",
                    "median survival": "9.5 months"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[10, 5, 36%, 18%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['48.4%', '20.6%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                    "treatment": "cell encapsulation + ifosfamide",
                    "control": "5-fluorouracil",
                    "phase": "2",
                    "median survival therapy": "10 months",
                    "median survival control": "5 months",
                    "one-year survival therapy": "36%",
                    "one-year survival control": "18%",
                    "side effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA approval": "n/a",
                    "toxicity": "five patients experienced Grade 3 or Grade 4 NCI toxicities with a higher dose of 2 g/m2",
                    "median survival": "9.5 months"
                },
                "measures": "[median survival therapy, median survival control, one-year survival therapy, one-year survival control]",
                "outcomes": "[10, 5, 36%, 18%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['10', '5']"
            },
            "match": "yes"
        }
    ],
    "total_extracted_claims": 5,
    "total_ground_truth_claims": 10,
    "number_of_matches": 4
}